How do you think doctors are going to react to their patients following the data from Iodine? There's a lot of room to misinterpret, especially when dealing with psychiatric drugs. Advil, Immodium, and Nyquil are pretty simple for people to report on: the thing that hurts stops == this drug worked (maybe).<p>Also, the one thing on the front page that made the largest impact on me is the brand name prevalence. If Iodine gets popular, that's going to have a direct effect on brand name sales. Would you be interested in doing more upfront comparisons between generic and brand names?<p>People will still buy brand name if it makes them feel better/safer/whatever of course, but a 200mg tablet of ibuprofen should have the same effects no matter who makes it (allergies/reactions from dyes and coatings not-withstanding). Shouldn't we be trying to educate patients about the science of it as well? That the same dosage of Advil vs. Generic is equivalent and teach people to save money?<p>>The investor enthusiasm for health ventures, said Halle Tecco, managing director of Rock Health, is fueled by the belief that the health care industry is both huge and technologically backward, and thus ripe for an assault with clever software and data-driven decision-making.<p>From my own experience, this could not be more correct.<p>I've been on three sides of the healthcare industry: nursing, surgical services, and now software. There is just a lot of old stuff piled on top of even older stuff. Some of that is reliable and necessary. Other times, it's a wonder the thing even works in the first place.<p>It's a wasteland of opportunity, so grab your hazard suit and start coding because me, my doctor and my optometrist personally think healthcare software currently sucks. :)